A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Eisai Inc.
Duke University
AstraZeneca
USWM, LLC (dba US WorldMeds)
GlaxoSmithKline
University of Oklahoma
NeoTX Therapeutics Ltd.
SystImmune Inc.
Merck Sharp & Dohme LLC
Vanderbilt-Ingram Cancer Center
Exelixis
Cancer Research UK
University of Alabama at Birmingham
Tempus AI
Ohio State University Comprehensive Cancer Center
Agenus Inc.
Carisma Therapeutics Inc
NextCure, Inc.
Revolution Medicines, Inc.
Comprehensive Support Project for Oncology Research